EM2201B "Treatment of Advanced Renal Cell Carcinoma" (IM GR-011422)
The purpose of this overview is to update the participants about the significant change in the treatment landscape for untreated advanced renal cell carcinoma over the last several years. The speaker will discuss the salient features of the new regimens which help in the discussion with kidney cancer patients and making individualized treatment decisions. Additional changes such as the approval of pembrolizumab in the adjuvant space are being discussed.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Name the major upfront regimens / combination immunotherapies for advanced renal cell carcinoma
- Be able to differentiate between the adverse effect and efficacy profiles of the PD1/CTLA4 vs the VEGF TKI/ PD1 combinations
- Describe some of the data and ongoing discussion about the use of pembrolizumab in the adjuvant space.
Hans Hammers, M.D., Ph.D.
Associate Professor, Department of Internal Medicine
Division of Hematology & Oncology
Dr. Hammers received his M.D. and Ph.D. degrees from the University of Lubeck in Germany. He completed a fellowship in Hematology and Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital in Baltimore, MD. He was an Assistant Professor at Johns Hopkins, when he was recruited to join the leadership of the KCP. In June of 2016, Dr. Hammers joined the faculty at UT Southwestern, where he is Associate Professor in the Department of Internal Medicine and Co-Leader of Clinical Research of the KCP. His research interest is in immunotherapies for kidney cancer. Dr. Hammers is the inaugural recipient of the Eugene P. Frenkel Scholar Award.
- 1.00 AMA